Halozyme (HALO) Price & Analysis

Compare

1,120 Followers

HALO Stock Chart & Stats

$68.10

$1.48(2.88%)

At close: Jan 08 4:00 PM EST

$68.10

$1.48(2.88%)

Day’s Range― - ―

52-Week Range$46.26 - $79.50

Previous CloseN/A

Volume1.23M

Average Volume (3M)2.17M

Market Cap

$8.01B

Enterprise Value$9.78B

Total Cash (Recent Filing)$701.96M

Total Debt (Recent Filing)$1.51B

Price to Earnings (P/E)14.3

Beta0.39

Next Earnings

Feb 24, 2026

EPS Estimate

1.9

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.72

Shares Outstanding117,597,000

10 Day Avg. Volume1,887,777

30 Day Avg. Volume2,165,663

Financial Highlights & Ratios

PEG Ratio0.21

Price to Book (P/B)16.67

Price to Sales (P/S)5.97

P/FCF Ratio12.95

Enterprise Value/Market Cap1.22

Enterprise Value/Revenue7.87

Enterprise Value/Gross Profit9.31

Enterprise Value/Ebitda11.03

Forecast

1Y Price Target

$77.63

Price Target Upside13.99% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering8

EPS Forecast (FY)6.27

Revenue Forecast (FY)$1.34B

Bulls Say, Bears Say

Bulls Say

Acquisition And Technology IntegrationHalozyme has successfully completed its acquisition of Elektrofi, Inc., a biopharmaceutical company with proprietary ultra-high concentration microparticle formulation technology.

Financial PerformanceHalozyme reported 3Q25 revenue of $354M, up 9% sequentially and ahead of the Street’s ~$340M estimate, with royalties rising 15% Q/Q to $236M.

Partnerships And CollaborationsThe collaboration with Merus is a signal that ENHANZE remains a highly sought-after technology in biopharma.

Bears Say

Acquisition RisksQuestions remain regarding the risk profile for Halozyme's proposed Elektrofi acquisition.

Commercial RisksRisks include commercial risk with ENHANZE, especially in the rapidly evolving multiple myeloma indication, and partnership risk with respect to Janssen.

Revenue Durability ConcernsInvestor concerns regarding revenue durability remain elevated due to CMS final guidance.

Halozyme News

Halozyme price target raised to $56 from $54 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Halozyme (HALO) to $56 from $54 and keeps a Neutral...

15d ago

HALO

Merus, Halozyme enter collaboration, license agreement for petosemtamab

Merus (MRUS) and Halozyme Therapeutics (HALO) announced they have entered into a global non-exclusive collaboration and license agreement....

16d ago

HALO

MRUS

Halozyme: JNJ gets FDA approval for new indication of DARZALEX Faspro

Halozyme Therapeutics (HALO) announced that Johnson & Johnson (JNJ) received U.S. FDA approval of a new indication for...

26d ago

JNJ

HALO

Halozyme announces two offerings totalling $1.3B in convertible senior notes

Halozyme (HALO) Therapeutics announced that it intends to offer, subject to market conditions and other factors, $650M aggregate...

28d ago

HALO

Halozyme price target raised to $92 from $91 at Citizens JMP

Citizens JMP raised the firm’s price target on Halozyme (HALO) to $92 from $91 and keeps an Outperform...

29d ago

HALO

Strategic Acquisition and FDA Approval Bolster Halozyme’s Market Position with a Buy Rating

Halozyme, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell Kapoor from H.C....

5d ago

HALO

Halozyme Announces CFO Transition Plan

The latest update is out from Halozyme ( ($HALO) ). On November 18, 2025, Halozyme Therapeutics, Inc. announced...

9d ago

HALO

Strategic Importance of Halozyme’s ENHANZE Platform and Its Growth Potential in Subcutaneous Drug Delivery

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Halozyme today and set a price target of...

14d ago

HALO

Halozyme Completes $1.5 Billion Convertible Notes Sale

Halozyme ( ($HALO) ) just unveiled an announcement. On November 12, 2025, Halozyme Therapeutics completed the sale of...

21d ago

HALO

Halozyme Announces Pricing of $1.3 Billion in Notes

Halozyme ( ($HALO) ) has issued an update. On November 6, 2025, Halozyme Therapeutics announced the pricing of...

26d ago

HALO

Halozyme Extends Credit Facility and Increases Commitments

Halozyme ( ($HALO) ) has provided an announcement. On November 5, 2025, Halozyme Therapeutics, Inc. announced an amendment...

28d ago

HALO

Halozyme Therapeutics’ Earnings Call Highlights Robust Growth

Halozyme Therapeutics (($HALO)) has held its Q3 earnings call. Read on for the main highlights of the call....

29d ago

HALO

Halozyme Therapeutics Reports Strong Q3 2025 Results

Halozyme Therapeutics ( ($HALO) ) has released its Q3 earnings. Here is a breakdown of the information Halozyme...

30d ago

HALO

Halozyme’s Strong Q3 Performance and Promising Future Drive Buy Rating

Analyst Brendan Smith of TD Cowen maintained a Buy rating on Halozyme, retaining the price target of $79.00....

30d ago

HALO

HALO FAQ

What was Halozyme Therapeutics’s price range in the past 12 months?

Halozyme Therapeutics lowest stock price was $46.26 and its highest was $79.50 in the past 12 months.

What is Halozyme Therapeutics’s market cap?

Halozyme Therapeutics’s market cap is $8.01B.

When is Halozyme Therapeutics’s upcoming earnings report date?

Halozyme Therapeutics’s upcoming earnings report date is Feb 24, 2026 which is in 83 days.

How were Halozyme Therapeutics’s earnings last quarter?

Halozyme Therapeutics released its earnings results on Nov 03, 2025. The company reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.63 by $0.09.

Is Halozyme Therapeutics overvalued?

According to Wall Street analysts Halozyme Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Halozyme Therapeutics pay dividends?

Halozyme Therapeutics does not currently pay dividends.

What is Halozyme Therapeutics’s EPS estimate?

Halozyme Therapeutics’s EPS estimate is 1.9.

How many shares outstanding does Halozyme Therapeutics have?

Halozyme Therapeutics has 117,597,000 shares outstanding.

What happened to Halozyme Therapeutics’s price movement after its last earnings report?

Halozyme Therapeutics reported an EPS of $1.72 in its last earnings report, beating expectations of $1.63. Following the earnings report the stock price went up 2.795%.

Which hedge fund is a major shareholder of Halozyme Therapeutics?

Currently, no hedge funds are holding shares in HALO

Halozyme Stock Smart Score

Outperform

Fundamentals

Return on Equity

124.50%

Trailing 12-Months

Asset Growth

4.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Halozyme Therapeutics

Halozyme Therapeutics, Inc. (HALO) is a biotechnology company specializing in the development and commercialization of novel therapeutics for patients with unmet medical needs. The company focuses primarily on drug delivery solutions and the development of enzymatic therapies that facilitate the subcutaneous delivery of biologics. Halozyme’s core product, Hylenex, is an injectable formulation of hyaluronidase that enhances the absorption and dispersion of other injected drugs, making it a valuable tool in various therapeutic areas including oncology and diabetes.

Halozyme (HALO) Earnings & Revenues

Historic Earnings Reports

HALO Company Deck

HALO Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call revealed strong financial performance driven by robust revenue growth from key subcutaneous therapies and strategic acquisitions. However, there are some challenges with collaboration revenue declines and pending acquisitions. Overall, the positive aspects significantly outweigh the negatives.View all HALO earnings summaries

HALO Revenue Breakdown

54.01% Royalties

36.28% Product sales

9.71% Revenues under collaborative agreements

HALO Stock 12 Month Forecast

Average Price Target

$77.63

▲(13.99% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"46":"$46","93":"$93","57.75":"$57.8","69.5":"$69.5","81.25":"$81.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$92.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":77.63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$77.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$56.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[46,57.75,69.5,81.25,93],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.19,67.2523076923077,69.31461538461538,71.37692307692308,73.43923076923076,75.50153846153846,77.56384615384616,79.62615384615384,81.68846153846154,83.75076923076924,85.81307692307692,87.87538461538462,89.93769230769232,{"y":92,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.19,66.14692307692307,67.10384615384615,68.06076923076922,69.0176923076923,69.97461538461538,70.93153846153845,71.88846153846154,72.84538461538462,73.80230769230769,74.75923076923077,75.71615384615384,76.67307692307692,{"y":77.63,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.19,64.48307692307692,63.776153846153846,63.06923076923077,62.36230769230769,61.65538461538461,60.94846153846154,60.24153846153846,59.534615384615385,58.82769230769231,58.12076923076923,57.41384615384615,56.706923076923076,{"y":56,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":57.15,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.59,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.81,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.64,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.87,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.64,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.92,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.94,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.19,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >